Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Accumulated Depreciation & Amortization (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Accumulated Depreciation & Amortization readings, the most recent being $253000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 64.37% to $253000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $253000.0, a 64.37% decrease, with the full-year FY2025 number at $253000.0, down 64.37% from a year prior.
  • Accumulated Depreciation & Amortization hit $253000.0 in Q4 2025 for Avalo Therapeutics, down from $710000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $710000.0 in Q4 2024 to a low of $253000.0 in Q4 2025.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $414000.0 (2022), compared with a mean of $441000.0.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 61.58% in 2021 and later plummeted 64.37% in 2025.
  • Avalo Therapeutics' Accumulated Depreciation & Amortization stood at $286000.0 in 2021, then soared by 44.76% to $414000.0 in 2022, then skyrocketed by 30.92% to $542000.0 in 2023, then skyrocketed by 31.0% to $710000.0 in 2024, then plummeted by 64.37% to $253000.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $253000.0 (Q4 2025), $710000.0 (Q4 2024), and $542000.0 (Q4 2023) per Business Quant data.